Compare Inovio Pharmaceuticals Inc (INO) vs Payoneer Global Inc (PAYO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Payoneer Global Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M), while Payoneer Global Inc trades at $7.14 (market cap $2.43B). The key difference: Payoneer Global Inc is far larger — about 21.7× Inovio Pharmaceuticals Inc's market cap, and Payoneer Global Inc is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Payoneer Global Inc for 61 Days on average.
| INO | PAYO | |
|---|---|---|
Market Cap | $112.19M | $2.43B |
Volume | 3,201,278 | 1,342,701 |
Sector | Health | Technology |
52-Week High | $2.65 | $7.18 |
52-Week Low | $0.66 | $4.27 |
Typical Hold Time | 43 Days | 61 Days |
Enterprise Value | $83.51M | $2.17B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO Pharmaceuticals trades at $1.09, down 5.63% today, with a bearish technical outlook despite positive analyst sentiment. The company faces significant fundamental challenges with minimal revenue of $65,340 in 2025 and substantial losses of $84.95 million. Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis, which could transform the company's prospects if approved.
Investment outlook hinges on FDA approval of INO-3107, with analysts maintaining a $2.75 consensus target representing 152% upside. However, persistent cash burn and negative profitability metrics pose substantial risks. The stock offers high-risk, high-reward potential for investors comfortable with binary regulatory outcomes in biotech.
Payoneer Global (PAYO) trades at $7.16 with a bullish technical signal supported by moving averages, though oscillators show neutral momentum. The company reported Q2 2026 earnings of $0.02 per share, missing estimates, but revenue grew 10% excluding interest. Recent news highlights the renewal of Payoneer's partnership with Etsy through 2029 and an agreement to be acquired by Nuvei, announced on June 15, 2026.
The outlook is mixed: analyst consensus is 60% buy with no sell ratings, but earnings misses and a high P/E of 51.18 pose valuation concerns. Key risks include integration challenges from the Nuvei acquisition and competitive pressures in fintech. Upside potential hinges on execution of B2B growth and expansion in India.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Payoneer Global Inc
Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started as a cross-border payments platform that empowers businesses, online sellers, and freelancers. The platform allows the users to get paid in multiple currencies, bill global clients, and sell on marketplaces worldwide.
Read more on PAYO →
